NCT03099603已完成1 期
A First in Human, Randomized, Double-Blind Study to Assess Safety, Tolerability, and Pharmacokinetics of Single, Ascending Doses of HTD1801 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) after single dose
研究概览
简要总结
This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age ≥18 to ≤ 50 years
- •Body mass index (BMI) ≥18.0 to ≤ 30.0 kg/m2
- •Current non-user of any nicotine containing products (>6 months)
- •Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for ≥12 months. The site will try to retrieve medical records to document the sterility, however, the absence of records will not exclude screening the participant. If medical records cannot be obtained, serum and urine pregnancy testing will be conducted. Postmenopausal status will be confirmed through testing of FSH levels ≥ 40 IU/mL at screening for amenorrheic female participants <50 years of age.
- •Males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent or if engaged in sexual relations with a child-bearing potential, the participant and his partner must be using an acceptable, highly effective, contraceptive method from Screening and for a period of 60 days after the last dose of Study Drug. Acceptable methods of contraception are the use of condoms and an effective contraceptive for the female partner that includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, or intrauterine contraception/device). The Principal Investigator will assess the adequacy of methods of contraception on a case-by-case basis.
- •Ability to provide written informed consent.
排除标准
- •Participation in an investigational drug study within 30 days prior to dosing or 5 half-lives within the last dose of investigational product whichever is longer.
- •Current use of any prescription or over-the-counter (OTC) medications, including herbal products and supplements, within 14 days prior to Day 1 or 5 half-lives, whichever is longer. [Use of ≤2 g per day of paracetamol (acetaminophen) is allowed prior to and during the study at Investigator discretion. The reason for use must be listed either in the subject's baseline information or as an adverse event.]
- •Any use of non-steroid anti-inflammatory drugs (NSAIDs) within 7 days prior to dosing.
- •History of any serious adverse reaction or hypersensitivity to any of the product components.
- •Use of parenterally administered proteins or antibodies within 12 weeks of screening. (Note: Influenza vaccine will be allowed)
- •Glucose-6-phosphate dehydrogenase(G6PD) deficiency.
- •History of weight loss > 5% in the 8 weeks prior to screening.
- •History of any active infection, other than mild viral illness, within 30 days prior to dosing.
- •History of alcohol or illicit drug abuse as judged by the Investigator within approximately 1 year
- •Use of any nicotine-containing product within 6 months prior to Screening or at any time during the study and follow-up as confirmed by urine cotinine screening.
- •Presence of clinically significant medical history, physical, laboratory, or ECG findings that, in the opinion of the Investigator, may potentially compromise the safety of the subject, or interfere with any aspect of study conduct or interpretation of results.
研究组 & 干预措施
0.5g
Placebo Comparator
single dose of placebo to 2 healthy subjects or 0.5g HTD1801 to 6 healthy subjects
干预措施: HTD1801 (Drug)
2.0g
Placebo Comparator
single dose of placebo to 2 healthy subjects or 2.0g HTD1801 to 6 healthy subjects
干预措施: HTD1801 (Drug)
4.0g
Placebo Comparator
single dose of placebo to 2 healthy subjects or 4.0g HTD1801 to 6 healthy subjects
干预措施: HTD1801 (Drug)
1.0g
Placebo Comparator
single dose of placebo to 2 healthy subjects or 1.0g HTD1801 to 6 healthy subjects
干预措施: HTD1801 (Drug)
结局指标
主要结局
Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) after single dose
时间窗: up to Day 30
Incidence, severity and causality of AEs and SAEs
次要结局
- PK of HTD1801 in plasma after single dose - area under the plasma concentration vs. time curve (AUC)(96 hours)
- PK of HTD1801 in plasma after single dose - half life (T1/2)(96 hours)
- HTD1801 plasma concentration levels after single dose(96 hours)
- Pharmacokinetics (PK) of HTD1801 in plasma after single dose - peak plasma concentration (Cmax)(96 hours)
- PK of HTD1801 in plasma after single dose - time to peak plasma concentration (Tmax)(96 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
SAD Phase I Study (First-in-human) to Investigate Contraloid AcetateAlzheimer DementiaAlzheimer DiseaseNCT03944460Prof. Dr. Dieter Willbold40
已完成
1 期
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and DiabetesDiabetes Mellitus, Type 2ObesityNCT05925920Metabolics Pharma49
已完成
1 期
First in Human Study of EI-001 Monoclonal Antibody in Healthy VolunteersHealthyNCT04994912Elixiron Immunotherapeutics (Hong Kong) Ltd.35
已完成
1 期
Single-ascending Dose Study of Kylo-11 in Healthy SubjectsCardiovascular DiseasesNCT06363851Kylonova (Xiamen) Biopharma co., LTD.71
已完成
1 期
Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a ComparatorHypoglycemiaNCT02367053Zealand Pharma111